Literature DB >> 261515

Limited proteolysis of complement components C2 and factor B. Structural analogy and limited sequence homology.

M A Kerr.   

Abstract

A method is described for the simultaneous purification of milligram quantities of complement components C2 and Factor B. Both products are homogeneous by the criteria of polyacrylamide-gel electrophoresis and N-terminal sequence analysis. Component C2 is cleaved by serine proteinase C1s at an X-Lys bond to give fragment C2a (approx. mol.wt. 74000) and fragment C2b (approx. mol.wt. 34000). The two fragments can be separated by gel filtration without the need for reducing or denaturing agents. Fragment C2b represents the N-terminal end of the molecule. Similar results were seen on cleavage of Factor B by Factor D in the presence of component C3. Again two non-covalently linked fragments are formed. The smaller, fragment Ba (approx. mol.wt. 36,000),) has threonine as the N-terminal residue, as does Factor B; the larger, fragment Bb (approx. mol. wt. 58000), has lysine as the N-terminal residue. A similar cleavage pattern is obtained on limited proteolysis of Factor B by trypsin, suggesting an Arg-Lys-or Lys-Lys bond at the point of cleavage. Although component C2 and Factor B show no apparent N-terminal sequence homology, a limited degree of sequence homology is seen around the sites of proteolytic cleavage.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 261515      PMCID: PMC1161643          DOI: 10.1042/bj1830615

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  20 in total

1.  Role of the second component of complement (C2) and plasmin in kinin release in hereditary angioneurotic edema (H.A.N.E.) plasma.

Authors:  V H Donaldson; F S Rosen; D H Bing
Journal:  Trans Assoc Am Physicians       Date:  1977

2.  The serine protease nature of the C3 and C5 convertases of the classical and alternative complement pathways.

Authors:  R G Medicus; O Götze; H J Müller-Eberhard
Journal:  Scand J Immunol       Date:  1976       Impact factor: 3.487

3.  N-terminal amino acid sequences of variant-specific surface antigens from Trypanosoma brucei.

Authors:  P J Bridgen; G A Cross; J Bridgen
Journal:  Nature       Date:  1976-10-14       Impact factor: 49.962

4.  The unactivated form of the first component of human complement, C1.

Authors:  I Gigli; R R Porter; R B Sim
Journal:  Biochem J       Date:  1976-09-01       Impact factor: 3.857

5.  The isolation and structure of C4, the fourth component of human complement.

Authors:  I Gigli; I von Zabern; R R Porter
Journal:  Biochem J       Date:  1977-09-01       Impact factor: 3.857

6.  Chemical characterization of human factor B of the alternate pathway of complement activation.

Authors:  B Curman; L Sandberg-Trägårdh; P A Peterson
Journal:  Biochemistry       Date:  1977-11-29       Impact factor: 3.162

7.  The purification and properties of the second component of human complement.

Authors:  M A Kerr; R R Porter
Journal:  Biochem J       Date:  1978-04-01       Impact factor: 3.857

8.  Cleavage of C2 by C1s into the antigenically distinct fragments C2a and C2b: demonstration of binding of C2b to C4b.

Authors:  S Nagasawa; R M Stroud
Journal:  Proc Natl Acad Sci U S A       Date:  1977-07       Impact factor: 11.205

9.  The assembly of early components of complement on antibody-antigen aggregates and on antibody-coated erythrocytes.

Authors:  J W Goers; R R Porter
Journal:  Biochem J       Date:  1978-11-01       Impact factor: 3.857

10.  Third component of human complement: purification from plasma and physicochemical characterization.

Authors:  B D Tack; J W Prahl
Journal:  Biochemistry       Date:  1976-10-05       Impact factor: 3.162

View more
  29 in total

1.  DNA polymorphism of the C2 locus.

Authors:  D R Bentley; R D Campbell; S J Cross
Journal:  Immunogenetics       Date:  1985       Impact factor: 2.846

2.  Isolation of cDNA clones for human complement component C2.

Authors:  D R Bentley; R R Porter
Journal:  Proc Natl Acad Sci U S A       Date:  1984-02       Impact factor: 11.205

3.  Degradation of human complement component C4b in the presence of the C4b-binding protein-protein S complex.

Authors:  B Dahlbäck; B Hildebrand
Journal:  Biochem J       Date:  1983-03-01       Impact factor: 3.857

Review 4.  The membrane attack complex.

Authors:  H J Müller-Eberhard
Journal:  Springer Semin Immunopathol       Date:  1984

5.  Amino acid sequence of the Bb fragment from human complement Factor B. Alignment of the cyanogen bromide-cleavage peptides.

Authors:  J Gagnon; D L Christie
Journal:  Biochem J       Date:  1983-01-01       Impact factor: 3.857

6.  Molecular cloning and characterization of the gene coding for human complement protein factor B.

Authors:  R D Campbell; R R Porter
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

7.  Fragment Bb in amniotic fluid: evidence for complement activation by the alternative pathway in women with intra-amniotic infection/inflammation.

Authors:  Edi Vaisbuch; Roberto Romero; Offer Erez; Shali Mazaki-Tovi; Juan Pedro Kusanovic; Kusanovic Juan Pedro; Eleazar Soto; Francesca Gotsch; Zhong Dong; Tinnakorn Chaiworapongsa; Sun Kwon Kim; Pooja Mittal; Percy Pacora; Lami Yeo; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2009-10

8.  The detection and characterization of a membrane protein with Factor B-like activity on human lymphoid cells.

Authors:  P Woo; P J Lachmann
Journal:  Immunology       Date:  1981-11       Impact factor: 7.397

9.  Human complement component C4. Structural studies on the fragments derived from C4b by cleavage with C3b inactivator.

Authors:  E M Press; J Gagnon
Journal:  Biochem J       Date:  1981-11-01       Impact factor: 3.857

10.  The reaction of iodine and thiol-blocking reagents with human complement components C2 and factor B. Purification and N-terminal amino acid sequence of a peptide from C2a containing a free thiol group.

Authors:  C Parkes; J Gagnon; M A Kerr
Journal:  Biochem J       Date:  1983-07-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.